STANDARD BIOTOOLS INC. - Common Stock, $0.001 par value per share (LAB)

CUSIP: 34385P108

Q4 2021 13F Holders as of 31 Dec 2021

Security type / class
Equity / Common Stock, $0.001 par value per share
Total 13F shares
56,282,734
Total 13F value
$220,394,393
Holder snapshot 6 visible 7 signals
Share change
-3,017,176
Put/Call ratio
51%
SEC-reported price per share
$3.92
Number of holders
116
Value change
-$14,652,768
Number of buys
49
Open additional details 1 more signal available
Number of sells
60
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
390,636,209

Security key

34385P108

Report period

Q4 2021

Institutions

116

Top holders

10

LAB full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2022 Previous quarter: Q3 2021 STANDARD BIOTOOLS INC. SEC filings STANDARD BIOTOOLS INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of LAB - STANDARD BIOTOOLS INC. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Indaba Capital Management...
Disclosed value leader
Indaba Capital Management...
Comparable rows
15/15
Latest evidence
30 Sep 2021
13F Lead comparable stake: 1.9% Showing 1-6 of 15 holder rows.

Quick read

Indaba Capital Management, L.P. leads the comparable SEC ownership view at 1.9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Indaba Capital Management, L.P.'s linked filing trail.
Comparable ownership Top 5
Indaba Capital Management, L.P. 1.9%
BlackRock Finance, Inc. 1.6%
PRIMECAP MANAGEMENT CO/CA/ 1.3%
ORBIMED ADVISORS LLC 1.2%
Neuberger Berman Group LLC 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Indaba Capital Management, L.P.
13F
Company
13F
1.9%
$49,071,000
7,446,229 shares
 — 30 Sep 2021
BlackRock Finance, Inc.
13F
Company
13F
1.6%
$41,851,000
6,350,729 shares
 — 30 Sep 2021
PRIMECAP MANAGEMENT CO/CA/
13F
Company
13F
1.3%
$34,683,000
5,263,043 shares
 — 30 Sep 2021
ORBIMED ADVISORS LLC
13F
Company
13F
1.2%
$30,311,000
4,599,571 shares
 — 30 Sep 2021
Neuberger Berman Group LLC
13F
Company
13F
1.1%
$27,714,000
4,280,190 shares
 — 30 Sep 2021
VANGUARD GROUP INC
13F
Company
13F
0.92%
$23,638,000
3,586,879 shares
 — 30 Sep 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
116
Shares
56,282,734
Rows available
116
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2021 vs Q3 2021 Across Filers

Q3 2021 holders
116
Q4 2021 holders
116
Holder diff
0
Investor Q3 2021 Shares Q4 2021 Shares Share Diff Share Chg % Q3 2021 value Q4 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .